Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “sector perform” rating restated by equities research analysts at Royal Bank Of Canada in a report released on Tuesday, reports.

Other research analysts also recently issued reports about the company. TD Securities decreased their price target on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a research note on Wednesday, June 8th. Scotiabank decreased their price target on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating for the company in a research note on Monday, July 25th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Valeant Pharmaceuticals Intl has an average rating of “Hold” and a consensus price target of C$38.83.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 35.82 on Tuesday. The firm has a 50-day moving average price of $36.04 and a 200-day moving average price of $38.29. Valeant Pharmaceuticals Intl has a 12 month low of $24.32 and a 12 month high of $299.06. The company’s market capitalization is $12.45 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Stock Target Prices

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.